Article, News
Prescient Therapeutics (ASX:PTX) partners with MD Anderson Cancer Center
Prescient Therapeutics (PTX) has partnered with the largest cancer centre in the US to create best-in-class, adaptable CAR-T cell therapies to treat certain cancer types.
Article, News
Prescient Therapeutics (ASX:PTX) locks in OmniCAR cell manufacturing contract for clinical trials
Prescient Therapeutics (PTX) has signed a manufacturing services agreement with Q-Gen Cell Therapeutics to produce its OmniCAR cell lines for its upcoming clinical trials.
News
Prescient Therapeutics (ASX:PTX) advances clinical programs in June quarter
Prescient Therapeutics (PTX) advanced multiple clinical programs for its targeted and cell therapy drugs over the June quarter.
News
Prescient Therapeutics (ASX:PTX) granted key US patent for OmniCar platform
Prescient Therapeutics (PTX) has been granted a key US patent for its OmniCAR universal immune receptor (UIR) platform.